Novel differentiation agents for AML1–ETO positive AML are targeted toward HDACs, which are capable of modifying the histone acetylation status by removing acetyl groups, thus leading to chromatin silencing. This evidence concerns the gene RUNX1 and acute myeloid leukemia.